CMV viraemia is associated with mortality among children with HIV starting antiretroviral therapy in sub-Saharan Africa

Clicks: 20
ID: 316544
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #419 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Cytomegalovirus (CMV) co-infection is associated with mortality in adults with HIV, but whether CMV is associated with mortality in children with HIV remains uncertain. METHODS: In 498 children (median age 6.3 years, interquartile range 2.3-9.6) enrolled in the ARROW trial (ISRCTN24791884) in Uganda (336/498) and Zimbabwe (162/498) selected using a case-cohort design, CMV was quantified using real-time polymerase chain reaction at initiation of non-nucleotide reverse transcriptase inhibitor-based antiretroviral therapy (ART), 12-weeks post-ART, and 84-weeks post-ART. Associations between baseline CMV viraemia and mortality were evaluated using multivariable models, adjusting for baseline HIV viral load, CD4+ percentage, and IL-6 concentrations. RESULTS: Baseline CMV viraemia was associated with mortality, with relationships differing by country and assay. In Zimbabwe (assay limit of detection 20 copies/mL), 119/162 (73%) children had detectable CMV, and each log10 higher CMV viral load was associated with over 2-fold higher mortality (adjusted hazard ratio (aHR)=2.74; 95% confidence interval (CI) 1.57-4.77). In Uganda (assay limit of detection 120 copies/mL), 89/336 (26%) children had detectable CMV viraemia, which was associated with 3-fold higher mortality compared to undetectable CMV (aHR=3.15; 95%CI 1.11-8.93). In a subset of 48 children with immunophenotyping data, we found no evidence that CMV was associated with immune activation. CONCLUSIONS: CMV viraemia is independently associated with mortality in children with HIV starting ART in sub-Saharan Africa. Future studies should define the underlying mechanisms and evaluate whether suppressing CMV viraemia reduces mortality in children with HIV.
Reference Key
openalex_W7164040051 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Temitope Fisayo, Ceri Evans, Kuda Mutasa, Dagmar Alber, Moira Spyer, Sandra Rukobo, Mutsa Bwakura-Dangarembizi, Victor Musiime, Kusum Nathoo, Adeodata Kekitiinwa, Cissy Kityo, Diana M Gibb, NJ Klein, A Sarah Walker, Andrew J. Prendergast
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag354
URL
https://doi.org/10.1093/cid/ciag354
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.